Clinical trials · Pennsylvania
Advanced or Metastatic Solid Tumors clinical trials in Pennsylvania
We’re tracking 385 recruiting advanced or metastatic solid tumors studies with a site in Pennsylvania — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT06730347RecruitingPhase 2
Study of lorigerlimab for advanced ovarian and other cancers
This trial tests a new drug, lorigerlimab, for people with certain types of ovarian cancer or related cancers that have come back or not responded to treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07216105RecruitingPhase 1
FT836 immune cell therapy for advanced solid tumors
This study tests a new immune cell therapy called FT836, given alone or with chemotherapy or other antibodies, for people with advanced solid tumors that have not responded to previous treatments. The goal is to see if it is safe and helps shrink or control tumors.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07433660Recruiting
WellSpan Cancer Quality of Life Study
This study looks at quality of life in people recently diagnosed with cancer. It aims to understand how cancer and its treatment affect daily life and well-being.
Ephrata, PennsylvaniaAges 18 years+ - NCT07470853RecruitingPhase 1
Study of HWK-016 for advanced ovarian or endometrial cancer
This trial tests a new drug called HWK-016, which is designed to target and deliver medicine directly to cancer cells that have a specific marker (MUC16). It is for people with advanced ovarian or endometrial cancer to see if it can shrink tumors or slow their growth.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Allentown, PennsylvaniaAges 18 years+ - NCT05677490RecruitingPhase 3
Chemo options, with or without nivolumab, for HER2-negative stomach cancer
This Phase 3 trial compares two standard chemotherapy regimens for advanced stomach, esophagus, or gastroesophageal junction cancer that is HER2-negative. It also tests whether adding nivolumab (an immune therapy) improves outcomes.
Allentown, PennsylvaniaAges 18 years+ - NCT06203600RecruitingPhase 2/Phase 3
Nivolumab plus standard treatment for advanced stomach or esophageal cancer
This trial tests whether adding the immunotherapy drug nivolumab to standard treatment works better for advanced stomach or esophageal cancer. It is for people whose cancer has already progressed after a first round of chemo plus immunotherapy.
Allentown, PennsylvaniaAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Philadelphia, PennsylvaniaAges 1–30 - NCT05263050RecruitingPhase 2
Trial tests a new cabozantinib schedule for kidney and neuroendocrine tumors
This Phase 2 study tests a different dosing schedule of cabozantinib (a cancer medicine) for metastatic kidney cancer and certain neuroendocrine tumors. It aims to see if the timing and schedule can work well for people with advanced disease.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05907980RecruitingPhase 1
ROSE12 alone and with other drugs for advanced solid tumors
This trial tests a new drug called ROSE12, given alone or with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapies. The study aims to see if ROSE12 is safe and effective.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05803382RecruitingPhase 1
Adding a new drug to capecitabine for metastatic colorectal cancer
This Phase 1 study tests a new anti-cancer drug (ZEN003694) added to the usual chemotherapy capecitabine. It is for adults with colorectal cancer (and possibly other cancers) that has spread or cannot be removed and has continued despite prior standard treatment.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06500455RecruitingPhase 3
Standard vs longer radiation for brain metastases
This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.
Allentown, PennsylvaniaAges 18 years+ - NCT07492641RecruitingPhase 3
A new drug plus letrozole for advanced HR+ breast cancer
This trial tests a new medicine (BGB-43395) combined with letrozole against the usual CDK4/6 inhibitor plus letrozole. It is for people with advanced or metastatic HR-positive, HER2-negative breast cancer who have not yet had treatment for advanced disease.
West Reading, PennsylvaniaAges 18 years+ - NCT07141706RecruitingPhase 1
Testing DB-1317 in advanced solid tumors
This trial tests an investigational drug (DB-1317) that targets a protein called ADAM9, found on some solid tumors. It is for people with advanced cancers that have not responded to other treatments, and aims to see if the drug is safe and works.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04469530RecruitingPhase 2
Sirolimus plus low-dose chemotherapy for high-risk childhood tumors
This Phase 2 study tests whether sirolimus combined with low-dose (“metronomic”) chemotherapy can help children and young adults with certain high-risk solid tumors stay in remission or reduce recurrence risk. It is designed for people whose cancer has responded well to initial treatment, with only minimal or no visible disease on scans.
Pittsburgh, PennsylvaniaAges 1–30 - NCT06885281RecruitingPhase 1/Phase 2
Study of ZL-1310 for neuroendocrine carcinoma
This trial is testing an experimental drug called ZL-1310 for people with neuroendocrine carcinoma (a rare, fast-growing cancer) that has spread or can't be removed. It aims to see if the drug is safe and works against the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04064359RecruitingPhase 1
Safety study of OBT076 for certain CD205+ solid tumors
This Phase 1 trial tests the safety of a new drug called OBT076 and looks for early signs it can help people with certain advanced (recurrent or metastatic) solid tumors that have a specific marker called CD205. You may be eligible if standard treatments are not available or no longer work, and your cancer meets lab and scan requirements.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05168163RecruitingPhase 2
Atezolizumab plus targeted drug for advanced liver cancer
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07185997RecruitingPhase 3
Testing firmonertinib for a type of lung cancer with rare EGFR mutations
This trial tests a new drug, firmonertinib, against other EGFR inhibitors as a first treatment for advanced lung cancer that has specific rare EGFR mutations (PACC mutations). It is for people who haven't had other treatments for their advanced cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06901531RecruitingPhase 3
Study of zolbetuximab with pembrolizumab and chemo for gastric cancer
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05372614RecruitingPhase 1
Testing trastuzumab deruxtecan and neratinib for HER2-positive cancers
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04796012RecruitingPhase 1/Phase 2
Atezolizumab plus chemo for children with recurrent solid tumors
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
Philadelphia, PennsylvaniaAges 6 months–30 years - NCT04114136RecruitingPhase 2
Study tests pembrolizumab or nivolumab plus a diabetes-like drug
This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06127407RecruitingPhase 3
Ivosidenib for advanced chondrosarcoma with IDH1 mutation
This trial tests an experimental drug called ivosidenib for people with a specific type of bone cancer (chondrosarcoma) that has spread or can't be removed with surgery. The drug targets a genetic change (IDH1 mutation) found in some chondrosarcomas. It may help slow or stop tumor growth.
Pittsburgh, PennsylvaniaAges 18 years+
Advanced or Metastatic Solid Tumors trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- Thomas Jefferson University Hospital · 5 studies
- UPMC Hillman Cancer Center · 5 studies
- Allegheny General Hospital · 3 studies
- Fox Chase Cancer Center · 3 studies
- Lehigh Valley Hospital - Muhlenberg · 3 studies
- Lehigh Valley Hospital-Cedar Crest · 3 studies
- Lehigh Valley Hospital-Hazleton · 3 studies
- Pocono Medical Center · 3 studies
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Advanced or Metastatic Solid Tumors trials in other states
Common questions
- Are there advanced or metastatic solid tumors clinical trials in Pennsylvania?
- Yes. We're currently tracking 385 recruiting advanced or metastatic solid tumors studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.